FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092581410> ?p ?o ?g. }

• W3092581410 endingPage "1982" @default.
• W3092581410 startingPage "1975" @default.
• W3092581410 abstract "BackgroundThis study evaluated the early and intermediate-term clinical and hemodynamic results after implant of the Medtronic 3F (Minneapolis, MN) stentless aortic valve.MethodsBetween March 2007 and August 2015, 226 consecutive patients affected by aortic valve disease received a 3F valve at our unit by a single surgeon. The valve in 30 patients was included in a tubular prosthesis for a Bentall procedure. Size ranged between 21 and 29, age at operation was 74.17 ± 8.58 years, mean logistic European System for Cardiac Operative Risk Evaluation was 9.73 ± 6.00, and 51.3% of patients received a concomitant procedure. For isolated valve replacement, mean extracorporeal circulation time was 92 ± 17 minutes, and cross-clamp time was 73 ± 11 minutes. Follow-up was 100% complete and was a mean of 63 ± 2.4 months (range, 6-138 months). Primary end points were early and late mortality, freedom from endocarditis, freedom from structural valve deterioration, and freedom from valve-related reoperation.ResultsEarly mortality after isolated aortic valve replacement was 1.7%. Of the 59 (25.3%) late overall deaths, 15 (6.6%) were cardiac-related, and survival rate was 93% at 10 years. At follow-up, 97% of patients were in New York Heart Association class I or II. Actuarial freedom from reoperation due to structural deterioration was 100% at 5 years and 96% at 10 years. Freedom from endocarditis at 10 years was 97%. Mean aortic pressure gradient measured by echocardiography was 11.5 mm Hg at hospital discharge and 10.4 mm Hg at the last follow-up.ConclusionsThe 3F valve is a user-friendly third-generation stentless aortic prosthesis with proven durability and remarkable hemodynamic performance preserved over time. The 3F is particularly useful in cases of expected patient/prosthesis mismatch This study evaluated the early and intermediate-term clinical and hemodynamic results after implant of the Medtronic 3F (Minneapolis, MN) stentless aortic valve. Between March 2007 and August 2015, 226 consecutive patients affected by aortic valve disease received a 3F valve at our unit by a single surgeon. The valve in 30 patients was included in a tubular prosthesis for a Bentall procedure. Size ranged between 21 and 29, age at operation was 74.17 ± 8.58 years, mean logistic European System for Cardiac Operative Risk Evaluation was 9.73 ± 6.00, and 51.3% of patients received a concomitant procedure. For isolated valve replacement, mean extracorporeal circulation time was 92 ± 17 minutes, and cross-clamp time was 73 ± 11 minutes. Follow-up was 100% complete and was a mean of 63 ± 2.4 months (range, 6-138 months). Primary end points were early and late mortality, freedom from endocarditis, freedom from structural valve deterioration, and freedom from valve-related reoperation. Early mortality after isolated aortic valve replacement was 1.7%. Of the 59 (25.3%) late overall deaths, 15 (6.6%) were cardiac-related, and survival rate was 93% at 10 years. At follow-up, 97% of patients were in New York Heart Association class I or II. Actuarial freedom from reoperation due to structural deterioration was 100% at 5 years and 96% at 10 years. Freedom from endocarditis at 10 years was 97%. Mean aortic pressure gradient measured by echocardiography was 11.5 mm Hg at hospital discharge and 10.4 mm Hg at the last follow-up. The 3F valve is a user-friendly third-generation stentless aortic prosthesis with proven durability and remarkable hemodynamic performance preserved over time. The 3F is particularly useful in cases of expected patient/prosthesis mismatch" @default.
• W3092581410 created "2020-10-15" @default.
• W3092581410 creator A5009291248 @default.
• W3092581410 creator A5030701676 @default.
• W3092581410 creator A5059660790 @default.
• W3092581410 creator A5077794285 @default.
• W3092581410 creator A5078698855 @default.
• W3092581410 date "2021-06-01" @default.
• W3092581410 modified "2023-09-24" @default.
• W3092581410 title "Intermediate-Term Outcomes After Aortic Valve Replacement With the Medtronic 3F Stentless Prosthesis" @default.
• W3092581410 cites W1994844315 @default.
• W3092581410 cites W1996412113 @default.
• W3092581410 cites W2009566698 @default.
• W3092581410 cites W2014116365 @default.
• W3092581410 cites W2046000040 @default.
• W3092581410 cites W2059371527 @default.
• W3092581410 cites W2073189672 @default.
• W3092581410 cites W2128973909 @default.
• W3092581410 cites W2131726356 @default.
• W3092581410 cites W2141539942 @default.
• W3092581410 cites W2296783629 @default.
• W3092581410 cites W2789789563 @default.
• W3092581410 cites W2804423083 @default.
• W3092581410 cites W2944443438 @default.
• W3092581410 cites W3044596489 @default.
• W3092581410 doi "https://doi.org/10.1016/j.athoracsur.2020.07.053" @default.
• W3092581410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33045206" @default.
• W3092581410 hasPublicationYear "2021" @default.
• W3092581410 type Work @default.
• W3092581410 sameAs 3092581410 @default.
• W3092581410 citedByCount "3" @default.
• W3092581410 countsByYear W30925814102021 @default.
• W3092581410 countsByYear W30925814102022 @default.
• W3092581410 crossrefType "journal-article" @default.
• W3092581410 hasAuthorship W3092581410A5009291248 @default.
• W3092581410 hasAuthorship W3092581410A5030701676 @default.
• W3092581410 hasAuthorship W3092581410A5059660790 @default.
• W3092581410 hasAuthorship W3092581410A5077794285 @default.
• W3092581410 hasAuthorship W3092581410A5078698855 @default.
• W3092581410 hasBestOaLocation W30925814101 @default.
• W3092581410 hasConcept C126322002 @default.
• W3092581410 hasConcept C141071460 @default.
• W3092581410 hasConcept C164705383 @default.
• W3092581410 hasConcept C178853913 @default.
• W3092581410 hasConcept C2775872228 @default.
• W3092581410 hasConcept C2776570981 @default.
• W3092581410 hasConcept C2778715743 @default.
• W3092581410 hasConcept C2779384505 @default.
• W3092581410 hasConcept C2780007028 @default.
• W3092581410 hasConcept C2780026749 @default.
• W3092581410 hasConcept C2780714102 @default.
• W3092581410 hasConcept C2781411149 @default.
• W3092581410 hasConcept C71924100 @default.
• W3092581410 hasConceptScore W3092581410C126322002 @default.
• W3092581410 hasConceptScore W3092581410C141071460 @default.
• W3092581410 hasConceptScore W3092581410C164705383 @default.
• W3092581410 hasConceptScore W3092581410C178853913 @default.
• W3092581410 hasConceptScore W3092581410C2775872228 @default.
• W3092581410 hasConceptScore W3092581410C2776570981 @default.
• W3092581410 hasConceptScore W3092581410C2778715743 @default.
• W3092581410 hasConceptScore W3092581410C2779384505 @default.
• W3092581410 hasConceptScore W3092581410C2780007028 @default.
• W3092581410 hasConceptScore W3092581410C2780026749 @default.
• W3092581410 hasConceptScore W3092581410C2780714102 @default.
• W3092581410 hasConceptScore W3092581410C2781411149 @default.
• W3092581410 hasConceptScore W3092581410C71924100 @default.
• W3092581410 hasIssue "6" @default.
• W3092581410 hasLocation W30925814101 @default.
• W3092581410 hasOpenAccess W3092581410 @default.
• W3092581410 hasPrimaryLocation W30925814101 @default.
• W3092581410 hasRelatedWork W1968968202 @default.
• W3092581410 hasRelatedWork W2150790103 @default.
• W3092581410 hasRelatedWork W2399066335 @default.
• W3092581410 hasRelatedWork W2400356234 @default.
• W3092581410 hasRelatedWork W2896034585 @default.
• W3092581410 hasRelatedWork W2903753411 @default.
• W3092581410 hasRelatedWork W3152261438 @default.
• W3092581410 hasRelatedWork W31565071 @default.
• W3092581410 hasRelatedWork W3196943402 @default.
• W3092581410 hasRelatedWork W4323019068 @default.
• W3092581410 hasVolume "111" @default.
• W3092581410 isParatext "false" @default.
• W3092581410 isRetracted "false" @default.
• W3092581410 magId "3092581410" @default.
• W3092581410 workType "article" @default.